CurrentPremera BluecrossPolicy 8.01.19

Nonpharmacologic Treatment of Hyperhidrosis

Defines medical necessity criteria for nonpharmacologic treatments of primary focal hyperhidrosis (axillary, palmar, plantar, craniofacial) and severe secondary gustatory hyperhidrosis, including which procedures are considered medically necessary versus investigational and documentation/billing guidance.

Policy Summary

PayerPremera Bluecross

PolicyNonpharmacologic Treatment of Hyperhidrosis

Policy CodePolicy 8.01.19

Change TypeTitle changebotulinum toxin moved to separate policyannual review (no policy changes)

Effective DateSep 1, 2025

Next Review Date

Key ActionDocument the affected area, presence of physical functional impairment or a qualifying medical condition and severity; for severe secondary gustatory hyperhidrosis document affected area and failed conservative therapy.

SourceLink

POLICY UPDATE CHANGES

Policy title changed to 'Nonpharmacologic Treatment of Hyperhidrosis' and botulinum toxin content removed to separate policy 5.01.512.

Annual review updated literature through May 1, 2025 with no change to policy statements.

4Primary focal regions with specified coverage guidance (axillary, palmar, plantar, craniofacial)

1Severe secondary gustatory hyperhidrosis covered option (tympanic neurectomy)

6Treatments labeled investigational across regions

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Overview: This policy (Nonpharmacologic Treatment of Hyperhidrosis, policy number 8.01.19) defines medical necessity criteria for nonpharmacologic treatments of primary focal hyperhidrosis (axillary, palmar, plantar, craniofacial) and severe secondary gustatory hyperhidrosis, indicating which procedures are medically necessary versus investigational and providing documentation and billing guidance. Status: CURRENT. Effective date: Sep. 1, 2025 (header shows Sep. 1, 2025; also lists Aug. 11, 2025 in document history).

Primary focal hyperhidrosis diagnostic features and HDSS

Primary focal hyperhidrosis diagnostic featuresVisible, excessive sweating ≥6 months plus at least 2 of: onset <25 years; bilateral symmetric sweating; cessation during sleep; frequency ≥ once/week; impairment of daily activities; positive family history

HDSS scale rangeHyperhidrosis Disease Severity Scale (HDSS) 1–4

HDSS threshold indicating significant impairmentScores 3–4 indicate sweating that frequently or always interferes with daily activities (barely tolerable/frequently interferes or intolerable/always interferes)

Coding

Covered CPT (procedures referenced in policy)CPTCovered

32664	Thoracoscopy, surgical; with thoracic sympathectomy
64818	Sympathectomy, lumbar
69676	Tympanic neurectomy

Other CPT codes historically referenced / removedCPT

11450	Previously added then removed (coding history)
11451	Previously added then removed (coding history)
64650	Previously referenced then removed
64653	Previously referenced then removed
97033	Application of modality; iontophoresis (added historically)

Provider Actions

Documentation Required

Document functional impairment or qualifying condition

Providers must document the affected area, the presence of physical functional impairment or one of the qualifying medical conditions (for example, recurrent infections or persistent eczematous dermatitis), and severity. For severe secondary gustatory hyperhidrosis, document the affected area and the conservative treatment trialed and failed.

Examples of qualifying conditions: recurrent skin maceration with bacterial or fungal infections; recurrent secondary infections; persistent eczematous dermatitis despite medical treatments.

Prior Authorization

Conservative therapy required prior to some surgical procedures

Prior conservative treatment must have failed before certain surgical procedures are considered (examples of conservative treatments include aluminum chloride 20% solution and botulinum toxin where specified).

Applicable procedure codes: 32664, 69676
Conservative therapy examples: aluminum chloride 20% solution; botulinum toxin (where noted in policy)

Billing Rule

Pharmacy vs medical benefit

Nonsurgical agents may be managed under the pharmacy benefit. Botulinum toxin has been removed from this policy and is covered under a separate policy (5.01.512).

Note: Botulinum toxin content removed from this policy and managed under policy 5.01.512.
Nonsurgical agents (e.g., topical antiperspirants, oral medications) may be pharmacy benefit items.

Background and Evidence Summary

Background and FDA status: The policy notes that topical aluminum chloride 20% solution is an FDA-approved treatment for primary hyperhidrosis.

Treatments summarized: Nonpharmacologic options addressed include iontophoresis, microwave therapies (e.g., miraDry), radiofrequency ablation (RFA), surgical excision of axillary sweat glands, endoscopic transthoracic sympathectomy (ETS), lumbar sympathectomy, and tympanic neurectomy, with evidence and policy statements varying by body region (some considered medically necessary when criteria are met; others investigational).

Secondary hyperhidrosis: For secondary hyperhidrosis, the policy emphasizes that treatment should target the underlying cause (for example, discontinuing causative drugs or treating underlying conditions); for severe secondary gustatory hyperhidrosis, tympanic neurectomy is listed as medically necessary if conservative therapy (e.g., aluminum chloride 20% solution) has failed and documentation of the affected area and failed conservative treatment is required.

Evidence Summary

Definitions

name	type	number	effective
Medicare National Coverage	NCD		none - no national coverage determination

Revision History

2023-11-01title_change_and_content_move

Policy title changed to 'Nonpharmacologic Treatment of Hyperhidrosis' and botulinum toxin content was removed from this policy and moved to separate policy 5.01.512.

2025-08-11annual_reviewLatest

Annual review updated literature through May 1, 2025 with no change to policy statements; coding history reflects prior removal of HCPCS 11450/11451 on May 1, 2025.